JNJ-38158471

Overview

JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor, with an IC 50 of 40 nM. JNJ-38158471 also inhibits Ret and Kit with IC 50 s of 180 and 500 nM, respectively.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > RET | Products > Signaling Pathways > c-Kit

Product Information

• Catalog No.: HY-18317
• CAS No.: 951151-97-6
• Molecular Formula: C15H17ClN6O3
• Molecular Weight: 364.79
• Purity: 97.02%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (6.85 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source